TY - JOUR
T1 - Urinary MMP-7
T2 - A Predictive, Noninvasive Early Marker for Chronic Kidney Disease Development in Patients with Hypertension
AU - Sarangi, Raj Laxmi
AU - Tripathy, Krishna Padarabinda
AU - Bahinipati, Jyotirmayee
AU - Gupta, Partisha
AU - Pathak, Mona
AU - Mahapatra, Srikrushna
AU - Mohapatra, Soumya R.
N1 - Funding Information:
We thank Dr. Pradip Kumar Pattnaik, principal, KIMS, for his immense support during the course of the study. We further thank all our study participants and laboratory technical staff for technical help. This work was supported by an internal grant from the Kalinga Institute of Medical Sciences, KIIT-DU, Bhubaneswar, India. All data generated during the current study are available upon reasonable request sent to the corresponding author.
Publisher Copyright:
© The Author(s) 2022. Published by Oxford University Press on behalf of American Society for Clinical Pathology. All rights reserved.
PY - 2022/7/1
Y1 - 2022/7/1
N2 - Objective: Upregulation of matrix metalloproteinase-7 (MMP-7) is associated with hypertension and kidney fibrosis, which can progress to chronic kidney disease (CKD). Currently, kidney fibrosis is only detectable by an invasive procedure. Therefore, we set out to determine whether MMP-7 can act as a noninvasive biomarker in patients with hypertension to enable early detection of kidney fibrosis. Materials and Methods: Diagnosed patients with hypertension and control patients were sampled. We diagnosed CKD using clinical and laboratory parameters. Serum urea, creatinine, urinary microalbumin, the albumin-to-creatinine ratio, and urinary MMP-7 were analyzed. Results: The 195 patients with hypertension had significantly elevated MMP-7. Of these patients, 166 had MMP-7 >25.8 μg/L, whereas only 29 had MMP-7 <25.8 μg/L. Thirty-two patients with hypertension showed features of CKD, all of whom had urinary MMP-7 >25.8 μg/L. However, the urinary MMP-7 level did not differ with the severity of CKD or with the duration of hypertension. Conclusion: Elevated urinary MMP-7 can be a potential noninvasive, early indicator in patients with hypertension progressing to CKD, thus enabling early therapeutic intervention.
AB - Objective: Upregulation of matrix metalloproteinase-7 (MMP-7) is associated with hypertension and kidney fibrosis, which can progress to chronic kidney disease (CKD). Currently, kidney fibrosis is only detectable by an invasive procedure. Therefore, we set out to determine whether MMP-7 can act as a noninvasive biomarker in patients with hypertension to enable early detection of kidney fibrosis. Materials and Methods: Diagnosed patients with hypertension and control patients were sampled. We diagnosed CKD using clinical and laboratory parameters. Serum urea, creatinine, urinary microalbumin, the albumin-to-creatinine ratio, and urinary MMP-7 were analyzed. Results: The 195 patients with hypertension had significantly elevated MMP-7. Of these patients, 166 had MMP-7 >25.8 μg/L, whereas only 29 had MMP-7 <25.8 μg/L. Thirty-two patients with hypertension showed features of CKD, all of whom had urinary MMP-7 >25.8 μg/L. However, the urinary MMP-7 level did not differ with the severity of CKD or with the duration of hypertension. Conclusion: Elevated urinary MMP-7 can be a potential noninvasive, early indicator in patients with hypertension progressing to CKD, thus enabling early therapeutic intervention.
KW - ACR
KW - biomarker
KW - chronic kidney disease
KW - eGFR
KW - fibrosis
KW - hypertension
KW - MMP-7
UR - http://www.scopus.com/inward/record.url?scp=85134083085&partnerID=8YFLogxK
U2 - 10.1093/labmed/lmac003
DO - 10.1093/labmed/lmac003
M3 - Article
C2 - 35246976
AN - SCOPUS:85134083085
SN - 0007-5027
VL - 53
SP - 386
EP - 393
JO - Laboratory Medicine
JF - Laboratory Medicine
IS - 4
ER -